• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds of the general formula and pharmaceutically acceptable non-toxic acid addition salts thereof, in which L and D, when applicable, define the chirality; R1 and R2 independently are hydrogen or C1-C3 primary alkyl; R3 is C1-C3 primary or secondary alkyl or-CH2CH2-S-CH3; R4 is hydrogen or C1-C3 primary alkyl; R5 is hydrogen or C1-C3 primary alkyl; Y is hydrogen or acetyl; and Zis -CH2OH, or -CN; subject to the limitation that one of R4 and R, is C1-C3 primary alkyl and the other is hydrogen; are useful analgesic agents.
    公开号:SU908246A3
    申请号:SU782669396
    申请日:1978-10-02
    公开日:1982-02-23
    发明作者:Ли Смитвик Эдвард (Младший)；Теодор Шуман Роберт；Куртис Артур Фредериксон Роберт
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    one
    This invention relates to a process for the preparation of tetrapeptides or their salts, new biologically active compounds that can be used in medicine.
    There is a method of releasing the corresponding protected peptides in an acidic medium. Using the known method allows to obtain new compounds with interesting pharmacological properties 1 1.
    The purpose of the invention is to obtain new derivatives of tetrapeptides or their salts that expand the arsenal of means of action on a living organism.
    The goal is achieved by the method of obtaining derivatives tetrapeptides formula
     O (o owr,
    Lf 1 p I N-CH-C-NH-CH-C-NW-CH, -C-W - C-Z
    I
    /., sn,
    R.
    where L and D mean chirality;
    R. - primary alkyl C .., - C-j; , K „- hydrogen or primary
    alkyl C - C3; RI is hydrogen or primary
    alkyl With
    1 CONH. (provided that one of the radicals Rj and primary alkyl, the second is hydrogen),
    or their salts, which means that the protected compounds corresponding to the tetrapeptide derivatives of the formula 1 are unblocked by treatment in an acidic medium.
    Moreover, the release is carried out in trifluoroacetic acid or in glacial acetic acid saturated with gaseous NSC.
    Pharmaceutically acceptable non-toxic acid addition salts include organic and inorganic acid salts, for example hydrochloric, sulfuric, sulfonic acid, tartaric, fumaric, hydrobromic, glycolic, citric, maleic, phosphoric, succinic, acetic, nitric, benzoic, acetic, acetic, nitric, nitric, benzoic, acetic, acetic, nitric, benzoic, acetic, acetic, nitric, nitric, benzoic, acetic, acetic, nitric, nitric, hydrobromic, hydrochloric, acid salts, acetic acid, acetic acid, nitric acid, hydrochloric acid phonic acids, naphthalenesulfonic acids and.
    propionic acid. It is preferable to choose hydrochloric, acetic or succinic acid to form acid salts. Any of these salts are obtained by known methods.
    The compounds of formula 1 are primary amides, primary alcohols or nitrile derivatives of specially defined tetrapeptides. The chirality of amino acid residues, when viewed from position 1 to 4 - oL, D, is absent. The residue in position 3 is the glycine group, therefore it cannot possess chirality. The residue in position 4 can be a primary amide, a primary alcohol, or a nitrile, its chirality is consistent with the corresponding putative L residue of an amino acid.
    Compounds of formula D are prepared using known peptide synthesis methods. It is possible that in the process of synthesis and some compounds of formula I, partial racemization occurs. However, the degree of racemization, if any, is insufficient to substantially change the anesthetic activity of compounds of formula I.
    Methods for preparing the α-compounds of formula I include the combination of amino acids or peptide fragments by reacting a functional group with another molecule to form an amide linkage. To ensure an effective combination, it is desirable that all reactive functional groups not directly involved in the reaction be deactivated by using appropriate blocking groups and the carboxyl functional group that is to be combined is activated appropriately to ensure the flow of the combination.
    All this requires careful selection of both the sequence of transformations and the reaction conditions, as well as the use of special blocking groups. Each of the amino acids that are used to obtain compounds of the formula I and which have specially selected protective groups and / or activated functional groups is obtained using known techniques.
    At each stage of the general synthesis of compounds of formula I, selected combinations of blocking groups are used; other combinations can work in the synthesis of compounds of formula I, although perhaps with a lower degree of efficiency. Thus, for example, benzyloxycarbonyl, t-butyloxycarbonyl, t-amyloxycarbonyl, 1-labels sibenzyloxycarbonyl, and queen and tyloxycarbonyl and isobornyloxycarbonyl can in various cases be used as groups of blocking amino groups in the synthesis of compounds of the formula. Moreover, the benzyl radical is usually used as a hydroxy protecting group for the tyrosyl residue. (Bzl), even if other agents can be used, for example p-nitrobenzyl, p-methoxybenzyl.
    Carboxyl-blocking groups used in the synthesis of compounds of formula 1 can be any of the typical ether-forming groups, for example, methyl, ethyl, benzyl, p-nitrobenzyl, p-methoxybenzyl, and 2,2,2-trichloroethyl.
    The combination of appropriately protected N-blocked amino acids or peptide fragments with respectively protected carboxy-blocked amino acids or peptide fragments in preparing compounds of Formula I consists in the conversion of free functional carboxyl groups of amino acids or peptide fragments active in a combination reaction ratio. This can be accomplished by using any of the known techniques, one of which is to convert the carboxyl functional group into a mixed anhydride. Free carboxylic functional groups are activated by interacting with another acid, usually a carboxylic acid derivative, such as an acid chloride. Examples of acid chlorides used to form mixed anhydrides are ethyl chloroformate phenyl chloroformate, sec-butyl chloroformate, isobutyl chloroformate and pivaloyl chloride. Isobutyl chloroformate is preferably used.
    Another way to activate the carboxyl groups for the purpose of the coupling reaction is to convert them to the corresponding active ester derivatives. Such active esters include, for example, 2,4,5-trichlorophenyl ester, pentachlorophenyl ester and p-nitrophenyl ester. Another method of coupling is the azide coupling method.
    The preferred combination method for preparing compounds of Formula I involves using N, S-dicyclohexylcarododimide (DSS) to activate the free carboxyl group and thereby facilitates the coupling reaction. This method is carried out using an equimolar amount of DSS relative to the amino acid or peptide fragment, and is carried out in the presence of an equimolar amount of 1-.oxy6-benzotriazole (frOBT). The presence of MBT suppresses undesirable side reactions, including probable racemization. Cleavage of selected blocking groups is necessary at certain stages in the synthesis sequence in preparing compounds of Formula G. Cleavage of carboxyl-protecting groups can be achieved by alkaline saponification. Typically, relatively strong alkalis are used to de-esterify the protected carboxyl, typically using alkali metal hydroxides (sodium hydroxide, potassium hydroxide and lithium hydroxide). Blocking carboxyl groups can also be removed by catalytic hydrogenolysis, for example, including hydrogenolysis in the presence of a catalyst - Palladium on coal. Moreover, in those cases. when the blocking carboxyl group is n-nitrobenzyl or 2,2,2-trichloroethyl, deblocking can be carried out by reduction in the presence of zinc and hydrochloric acid. The groups that block the amine function are cleaved by treating the protected amino acid or peptide with an acid, such as formic acid, trifluoroacetic acid (TFA), p-toluenesulfonic acid (TSC), benzenesulfonic acid (BSC), and naphthalene sulfonic acid to form the salt of the addition salt with the corresponding sour you. Aminoblocking group cleavage can also be carried out by treating the blocked amino acid or peptide with HB-g mixture. or HC and acetic acid in order to obtain the corresponding acid addition salt, hydrobromide or hydrochloride. The particular method or reagents used depend on the chemical or physical characteristics of the materials used in the special release reaction. In cases where the group R is different from hydrogen and the peptide contains at least three amino acid residues that should be unblocked, it is most preferable to unlock the TFA peptide or formic acid to obtain the corresponding acid addition salt. This salt can be converted to a more pharmaceutically acceptable neutral form by treating with an appropriate ion exchange resin, for example DEAE, Sephadect A25 and Amberlite A27. The oxy-protecting group present in the tyrosyl residue can be retained in the peptide during the successive stages of its preparation, and it is removed at the last stage of the synthesis in combination with the cleavage of amine-blocking groups. However, 1, depending on the conditions used to remove carboxyl blocking groups, it can be removed earlier in the preparation process. When the carboxyl group is cleaved by alkaline decoupling, the oxy-protecting group is retained, however, using catalytic hydrogenolysis to remove the carboxyl-protecting group, the protecting group is also cleaved off. But the preparation of compounds of formula I can be carried out in the presence of a tyrosyl residue having a free hydroxyl group. Example 1. Preparation of L-tyrosyl-0-ananine-glycyl-No-methyl-1.-Phenylalaninamide (acetic acid salt). A. Benzyl-B-alinate-p-toluenesulfonate. To a mixture of 100 ml of benzyl alcohol and 200 ml of benzene, containing 55.1 g (0.29 mol) of p-toluenesulfonic acid monohydrate, was added 25 g (0.01 mol) of D-alanine. The mixture is brought to a boil, and the water is removed as an azeotrope using a Dean-Stark trap. This mixture is heated for 15 hours and then cooled to room temperature and diluted with ether. The precipitate obtained is separated and recrystallized from a mixture of methanol and ether to obtain 55.3 g (56%) of the compound, m.p. 112-115 ° C. Molecular weight 351.42. Elemental analysis: Scored,%: C 58.10; H 6.02; N 3.99. C I,;, N05 Found,%: C 58.19; H 6.06; N 3.82. B. Benzyl-N - tert.-butyl cicarbonyl-O-benzyl-L-tyrosyl-P-alinate. To 200 ml of dry dimethylformamide (DMF) was added 35.1 g (0.1 mol) of diazabicyclooctane (DABCO). The mixture is stirred for 10 minutes at 0 ° C and 37.1-g (0.1 mol) N-Tpet.-butyloxycarbonyl-o-benzyl.-Tyrosine is added and then 13.5 g (0.1 mol) 1 -oxybenzotriazole (HBT) and 20.6 g (0.1 mol) N, H-dicyclohexylcarbodiimide (DS.S). The resulting mixture was stirred at 0 ° C for 3 hours and then at room temperature for 1 day. Then the mixture is cooled to, the resulting suspension is filtered and the filtrate is concentrated in vacuo. The precipitate was redissolved in ethyl acetate and washed successively with 1N. NaHCO3f solution with water, cold 0.75 n. citric acid solution and water. The organic layer is dried over magnesium sulfate, filtered and concentrated in vacuo. The residue obtained is dissolved in hot ethanol. Crystallization occurs upon cooling. After the first crystallization from ethanol, 41.5 g (80%) of the pure substance are obtained; mp. 121-123 C. Molecular ec 520.63,
    Elemental analysis:
    Calculated,%: C, 69.21; H, 6.97; N, 5.38 CsoN3bNgOb
    Found%: C 68.99; H 6.75: N 5.17
    B. No.-tert.-butyloxycarbonyl-0benzyl-b-tyrosyl-B-alanine.
    To a mixture of 200 ml of tetrahydrofuran (THF) and 20 ml of water was added 31.2 g (0.06 mol) of the obtained product. The resulting solution is cooled to 0 ° C and 13.2 ml (1.1 equivalents} of 5N sodium hydroxide solution is slowly added. The mixture is stirred and allowed to slowly warm to room temperature. The mixture is distributed between ether and aqueous layers. The aqueous layer is separated and cooled, maintaining the pH by adding citric acid, and the mixture is extracted with ethyl acetate. The ethyl acetate extract is washed with water, dried over magnesium sulfate, filtered and diluted with ether. The resulting precipitate is collected to give 17.7 g (67%) connect Nb, mp 1bO-1b2 ° C. Molecular weight 442.51.
    Elemental analysis:
    Calculated,%: C 65, 6, B3; N 6.6 C24H3oN2.0b
    Found: C, 64.73; H, 6.70; N, 6.20
    G. Benzyl-M -tret. -butyloxycarbonyl-O-benzyl-L tyrosyl-0 - alanyl glycinate.
    To 70 ml of dry DMF was added 6.74 g (0.02 mol) of the acidic p-toluenesulfonic acid salt of benzyl glycinate. The mixture was cooled to 0 ° C and 2.24 g (0.020 mol) of DABCO was added. The mixture was stirred for several minutes and 8.84 g (0.020 mol) of the obtained product was added, followed by 2.7 g (0.020 mol) of HBT and 4.12 g (0.020 mol) of DCC. The reaction mixture is stirred for 2 hours at 0 ° C and then for 1 day at room temperature. The resulting suspension is cooled to wasps, filtered and the filtrate is concentrated in vacuo. The resulting precipitate is dissolved in ethyl acetate and washed successively with 1N. sodium bicarbonate solution, water, cold 0.75 n. citric acid solution and water. The organic phase is dried over magnesium sulphate, filtered and concentrated in vacuo. The resulting residue is crystallized from ethanol to give 10.8 g (92.8%) of the pure compound, m.p. 145 147С. Molecular weight 589.69.
    Elemental analysis:
    Calculated,%: C, 67.22; H, 6.67; N, 7.1 Cji Nzey O,
    Found: C, 67.32; H, 6.83: N, 6.9
    D.-butyloxycarbonyl-Obensyl-1. -Tyrosyl-B-alanyl glycine.
    15.95 g (27 mol) of the obtained product is added to 150 ml of a mixture of tetrahydrofuran and water (9: 1). The mixture is cooled to OC with stirring and 30 ml of 1N is added dropwise to the mixture. sodium hydroxide solution. The mixture is stirred for 2 hours until completion of delivery.
    and then it is extracted twice with ether. The separated aqueous layer is acidified to a pH of 2.5 by adding 30 ml of 1N. hydrochloric acid solution. The substance is crystallized, filtered off and recrystallized.
    5 once from a mixture of methanol and water and twice from ethyl acetate, yielding 11.43 g (85% of theory), m.p. 104-107 ° C.
     31.4 ° (, 5; methanol). Molecular weight 499.54.
    Elemental analysis:
    Calculated,%: C 62.51; H, 6.66; N 8.41
     Njo
    Found,%: C 62.31; H, 6.83; N 8.12. 5 E..-Butyloxycarbonyl-No. Methyl-1-phenyl-alanine, d (+) - methylbenzylamine salt.
    13.26 g (0.05 mol) .0 butyloxycarbonyl-c-phenylalanine was added to 75 ml of tetrahydrofuran, and the resulting mixture was added dropwise within 30 minutes to a suspension of 0.15 mol of potassium hydride and 0.5 g during 30 minutes. 18-krau-6 ether with
    5 under nitrogen. Stirring is continued at 0 ° C for another 1 hour. A solution of 6.23 ml (0.1 mol) of methyl iodide in 15 ml of tetrahydrofuran is added dropwise over 15 minutes.
    0 The mixture is aged for 2 hours and a mixture of 10 ml of acetic acid and 10 ml of tetrahydrofuran is added dropwise and then 20 ml of ethanol is added. - The mixture is then poured into 400 ml of ice. The pH of the resulting aqueous phase is adjusted to 12-13 by the addition of 2N sodium hydroxide solution. The aqueous mixture is extracted twice with ether and then acidified to pH 3.0 by adding solid citric acid. Then the aqueous mixture is extracted with ether- (3 X 200 ml). The ether extracts are combined, extracted with water, dried over magnesium sulphate and evaporated in vacuo to a syrupy state. This syrup is dissolved in 50 ml of ether and 6.44 ml (0.05 mol) of d (+) - o-methylbenzylamine is added. The product is precipitated by addition of 350 ml of hexane, filtered off, 15.83 g (79% of theory) of the compound are obtained. Recrystallization from ethyl acetate gives 13.70 g (68% of theory) of the compound, mp; 136 .139 ° С; ct - 28.2 (C-1, ethanol).
    5 Molecular weight 400.50, Elemental analysis: Calculated,%: C 68.97; H 8.05; N 6.9 q2i Found,%: C 68.75; H 7.81; N 6.7 J.  . -butyloxycarbonyl-methyl methyl-b-phenylalanilamide.  N is tert. -butyloxycarbonyl-N-methyl-i-phenylalanine (4 g, 0.01 mol) obtained by acidification of the d (t) -methylbenzylamine salt and followed by extraction with ether, was dissolved in 20 ml of DMF.  The mixture is cooled to -5 ° C and 1.56 ml (0.012 mol) of isobutyl chloroformate and then 1.32 ml (0.012 mol) of N-methylmorpholine are added.  The reaction mixture is stirred for a period of 10 minutes at which anhydrous carbon dioxide is bubbled into it for 1.5 h.  The resulting mixture is stirred for 1 hour at and then poured into a vessel containing 200 ml of ice.  An aqueous solution of extras is aggravated with ethyl acetate.  The organic layer is separated and washed successively with 1.5N.  citric acid solution, water, 1 n.  a solution of bica bonate sodium and water.  The ethyl acetate solution is then dried over magnesium sulphate and evaporated in vacuo to a syrupy state.  The syrup crystallizes from a mixture of ether and petroleum ether, to obtain 2.12 g (76% of theory) of compound t.  square  91 - 92 ° C, laL: i - 111.2 (C 0.5 CHC6j).  Molecular weight 278.33.  Elemental analysis: Calculated,%: C 64.73; H 7.97; N 10, C 5-% CN203 Found,%: C 64.95; H 7.8l; N 9.7 3 .  . -butyloxycarbonyl-Obensyl-1-tyrosyl-O-alanylglycyl-No. methyl-phenylalanilamide.  To 20 ml of freshly prepared ice-cold, acetic acid containing anhydrous hydrogen chloride (1N. solution and 2 ml of anisole, to & 1.95 (0.007 mol) N-weave. -butyloxycarbonyl-H methyl-b-phenylalanilamide.  The resulting mixture was stirred at room temperature for 30 minutes.  Then it is poured into ether, the precipitated precipitate is separated, dried, 1.5 g of hydrochloride salt are obtained, which is dissolved in 30 ml of DMF.  The solution is cooled to 0 ° C and 1.4 ml (0.007 mol of dicyclohexylamine) are added to it.  The mixture was stirred for several minutes and 3.5 g (0.007 mol) was added. -butyloxycarbonyl-0-benzyl-tyrosyl-P-alanylglycine, 950 mg (0.007 mol) HBT and 1.4 g (0.007 mol DOS.  The reaction mixture is then stirred for 2 hours and then at. within 1 day, freshly cooled to and filtered.  Fil. the concentrate is concentrated in vacuo to an oily state; the oil is redissolved in ethyl acetate. The ethyl acetate solution is subsequently extracted with 1N.  sodium bicarbonate solution, water, cold 0.75 n solution.  citric acid and water.  The organic phase is dried over magnesium sulphate and concentrated in vacuo to an oil.  The oil is subjected to chromatographic purification on a 40 cm x 3 cm column with Grace Silikel and Davison 62 silica gel in chloroform.  Elution product using a step gradient of chloroform concentration in a mixture of 10% methanol in chloroform.  Monitoring the progress of cleaning is carried out using thin-layer chromatography of the selected fractions.  3.55 g (77% of theory) of the compound are obtained,, - 9.2 (C O, 5; methanol).  Molecular weight 659.8.  Elemental analysis: Calculated,%: C 65.54; H 6.57; il 10.61 C H N O O Found,%: C 65.46; H 6.58; N 10.36 I.  1 P -tret. -butyloxycarbonyl1. -tyrosyl-P-alanyl-glycyl-K -methyl-L-phenylalanilamide.  3.2 g of the obtained product (0.0485 mol) are dissolved in 60 ml of ethanol and 1.5 g of palladium (5%) on coal are added to the mixture as an aqueous suspension.  Nitrogen was bubbled through the reaction mixture using a gas distribution tube for 5 minutes and then hydrogen was passed in for 6 hours.  The reaction mixture is then flushed with nitrogen and the palladium catalyst is filtered off.  The mixture is concentrated in vacuo to a syrupy state.  The syrup is dissolved in chloroform and passed through a 40 X 3 cm chromatographic column containing Grace silica gel and Davison 62.  The product was eluted using a stepwise gradient of chloroform concentration in a mixture of 10% methanol in chloroform and recovered according to the thin-layer profile of the selected fractions, to give 2.0 g of compound (74% of theory), 9.9 (, 5 methanol).   Amino acid composition-gssu 1.01, Aba 0,99; Tough 0.99; ННз 1,14.  . TO; . 4j-tyrosyl-1) -alanyl-glycylN-methyl-L-phenylalanilamide, acetate salt.  1.6 g of the obtained product (0.00281 mol) is dissolved in 10 ml of TFA containing 0.5 ml of anisole.  The mixture was stirred at 0 ° C for 30 minutes, then poured into ether and the resulting precipitate was collected and dried (1.1 g).  The solid is dissolved in an appropriate amount of an aqueous buffer solution (1% pyridine and 0.05% acetic acid) to a volume of 15 ml and the solution is passed through a DEAE-Seph column. A-25 (acetate) with a size of 2.5 X 99 cm, balanced by the same buffer.  The eluate was observed at 280 nm and the corresponding fractions were collected and lyophilized. By repeated lyophilization of 10% acetic acid, followed by lyophilization from a mixture of water and acetonitrile (3: 1), 0.84 g of the compound is obtained.   + -27.8 (C 1.1 n.  HC solution Amino acid composition: Tough 0.98 1.03; sew 1.00; YNS 1.05.  II p and me 2.  Preparation of L-tyrzyl-0-alanyl-glycyl-L-c-methylphenyl alanyl amide, acetate salt.  BUT.  L-o-methylphenylalanine, benzyl ether, tosylate salt.  3.0 (0.0188 mol) L-bt-methylphenylalanalan is added to 100 ml of benzene. To this suspension is then added 3.5 g (1.1 equivalents) of p-toluenesulfonic acid hydra and 10 ml of benzyl alcohol.  The mixture was heated under reflux and a Dean-Stark trap for water for 4 s. Then the mixture was cooled to room temperature and ether was added to it to precipitate the tosylate salt.  The resulting precipitate was collected and dried to give 7.0 g (94%) of the compound, t.  square  129 - 131 ° C.  bU | f- 10.7 ° (C 0.5; 1 n.  solution in methyl alcohol).  Molecular weight 441.5.  Elemental analysis: Calculated,%: N 3.17 N GS Found,%: N 2.87.  B.  N-tert. -butyloxycarbonyl-Obensyl-L-tyrosyl-B-alanyl-glycyl-LOC-methylphenylalanine, benzyl ester To 80 Nm DMF, 5.74 g (0.013 mol) of the obtained product was added.  The mixture was cooled to 5 minutes and 6.5 g (13 mol) was added.  No. -tert-butyloxycarbonyl 0-bin: zyl-b-tyrosyl-0-alanyl-glycine (obtained as in example 1), 1.8 g (13 mol) of HBT and 2.7 g (13 mo DSS.  The mixture is stirred for 2 hours and then at room temperature for 1 day.  The mixture is then cooled to 0 ° C and the resulting precipitate is separated by filtration.  The filtrate is evaporated in vacuo.  The resulting residue was dissolved in ethyl acetate, and the ethyl acetate solution was sequentially extracted with 1N.  sodium bicarbonate solution, water, 0.75 n.  with an aqueous acid solution and water. The organic layer is then dried over magnesium sulphate and evaporated in vacuo to an oily state. The oil is crystallized from ether and recrystallized from a mixture of ethyl acetate and ether.  7.0 g are obtained (72% of compound: i.  W.  +7.9 (C 0.5 methanol).  Molecular weight 750.86; Elemental analysis: Calculated,%: C 68.78 ;;; 6.7l; N 7.46; Found. .  %: C 68.75; H 6.46; N 7.21.  AT.  . -butyloxy-arbonyl-tyrosyl-B-alanyl-glycyl-b-o1-methylphenylalanine, dicyglohexylamine salt.  To 50 ml of ethanol was added 4.0 g (0.053 mol) of the obtained product.  A suspension of 2.0 g of palladium (5%) on carbon in DMF is then added.  Nitrogen fed through a gas distribution tube for 5 minutes is passed through the mixture, and then hydrogen gas is supplied for 4.  The mixture is then extensively flushed with nitrogen and the palladium catalyst is separated by filtration.  The filtrate is concentrated in vacuo to a syrupy state.  Chloroform solution syrup is fed to a 10 x 2 cm column, which carries Grace and Davison 62 silica gel.  The column was eluted with a stepwise gradient of chloroform concentration in a mixture of chloroform and methanol (9 at 5: O, 5).  The main fractions are combined and the solvent is evaporated.  The resulting oil is dissolved in ethyl acetate and added to the plant. Thief 1 ml dicyclohexylamine.  The precipitated product is filtered off, dried, yielding 2.6 g (65%) of the compound, t.  square  142 - d +46.3 (C 0.5, methanol).  G.  N -t. -butyloxycarbonyl-tyrosyl-O-alanyl-glycyl-b-o-methylphenylalanilamide.  2.0 g of the obtained product (0.0227 mol) is neutralized with a mixture of ethyl acetate and 0.75 n.  citric acid solution.  The separated organic layer is separated, extracted with water, dried over magnesium sulphate and evaporated in vacuo to an oil (1.5 g).  The resulting free acid is dissolved in 30 ml of DMF and the solution is cooled to 0 ° C in a pressure resistant bottle.  560 mg of DSS (0.0027 mol) was added and the mixture was stirred for 4 hours at 0 ° C and then for 3 hours at room temperature.  The bottle is then cooled to-78 ° C and 30 ml of anhydrous ammonia are added.  The bottle is sealed again and the mixture is allowed to stir at room temperature for 48 hours.  The mixture is cooled to -78 ° C, the bottle is opened and unreacted ammonia is degassed by heating the bottle to room temperature.  Then the solvent is evaporated in vacuo.  The resulting residue was dissolved in ethyl acetate, and the ethyl acetate solution was first extracted with 0.75 n.  citric acid solution and then water.  The solution is dried over magnesium sulfate, and the solvent is evaporated in vacuo.  The residue was dissolved in chloroform and fed to a 3 x 45 column with silica gel.  The column was eluted with a gradual gradient involving the addition of chloroform to a mixture of chloroform - methanol (9: 1).  Monitoring the progress of cleaning lead using chromatography in a thin layer.  The fractions containing the product are combined, evaporated, and 1.1 g (72%) of the compounds are obtained, 26 ° (C 4, methanol) Amino acid analysis: G € y 0.99J ACa 1.00; Tough 0.99; YHL 1.12.  D.  L-tyrosyl-O-alanyl-glycyl-L-ci-methylphenylalanilamide, acetate salt.  To 20 ml of a mixture of 1 n.  a solution of hydrogen chloride in glacial acetic acid containing 0.3 ml of anisole was added 0.9 g (0.0016 mol) of the obtained product.  The mixture is stirred at room temperature for 30 minutes and then poured into ether.  The precipitated K is collected and dried (720 mg).  The solid is dissolved in such an amount of a buffer solution (1% pyridine and 0.05% acetic acid) so that the final volume is 5 ml and the solution is fed to a 2.5 cm x 99 cm column with DEAE-Sephadex A-25 (acetate), pre-equilibrated with the same buffer.  The eluate is viewed at 2 0 with them and the corresponding fractions are combined and lyophilized.  Repeated lyophilization was carried out with 10% acetic acid and then from a mixture of water and aceto-nitrile (3: 1).  400 mg of compound are obtained 23.9 ° (C 0.5; 1 n.  solution neb).  Molecular weight 529.60.  Elemental analysis; Calculated,%: C 58.97; H 6.66; N 13.22; About 21.15.  S2bNz5% 07 Found,%: C 59.02) H 6.36, N 12.99; About 21.41.  Amino acid analysis: Tug 0.96) Aba l, 0i; Ggy 1.00; NHj 1.03.  Froze  Preparation of L-tyrosyl-B-alanyl-glycyl-E n-propyl-bphenylalanilamide, acetate.  BUT.  N -t. -butyloxycarbonylN -n-propyl-b-phenylalanine.  10.6 g (0.04 mol) was added to 70 ml of tetrahydrofuran. -Byloxycarbonyl-b-phenylalanine and the resulting mixture is added dropwise over 30 minutes with vigorous stirring to a suspension of 0.12 mol of potassium hydride in 220 ml of tetrahydrofuran and 0.5 g of 18-crown-6 ether at.  The process is conducted in a nitrogen atmosphere.  The mixture is stirred for another 10 min.  A solution of 23.3 ml (0.24 mol) is added dropwise. ) 1-iodopropane 40 ml of tetrahydrofuran for 20 minutes.  The mixture is kept. for 2.5 hours at and 11.5 ml (0.12 mol) of 1-iodopropane are added dropwise to it.  Stirring is continued for another 2 hours at, then 10 ml of glacial acetic acid are added and mixed again for 10 minutes.  The mixture is then poured onto crushed ice.  The pH of the resulting aqueous phase was adjusted to 8.0 by adding 2N. sodium hydroxide solution.  The aqueous phase is extracted twice with ether and then acidified to pH 2.5 by the addition of cold 2N.  solution NSB.  Then the aqueous phase is extracted with ethyl acetate.  The ethyl acetate extract is washed once with water, dried with magnesium sulfate and evaporated in vacuo to a syrupy state.  The syrup is dissolved in 200 ml of ether and 8 ml, (0.04 mol) of DCHA is added.  The precipitate O1-filtered and the filtrate is washed 1 ,.  5 n.  citric acid solution and oxen.  The ether layer is dried over magnesium sulfate and evaporated in vacuo to an oily state.  The oil is purified by chromatography on a 3 x 40 cm column with silica gel in chloroform-.  The product was eluted using a step gradient of chloroform in a mixture of 5% methanol in chloroform.  The progress of cleaning is monitored by thin layer chromatography.  The fractions containing the product are collected and evaporated to give 3.6 g (31% of theory) of the compound, aL - 153.3 (C - 1 methanol).  NMR spectrum: cG () 10.47; cG (MeSS-) 1.50.  Molecular weight 295.4.  Elemental analysis: Calculated,%: C 65.06; H 8.53; 4.74 C.  Found,%: C 65.2b; H, 8.29; N4,69 B. . -butyloxycarboxylN -n-propyl-b-phenylalanilamide.  To solution m-tert. -butyloxycarbonyl-n-propyl-L-fevilanine in DMF, cooled to -15 ° C, one equivalent of isobutyl chloroformate and then one equivalent of N-methylmorpholine is added.  The mixture is stirred for 10 minutes at -15 ° C. and then anhydrous ammonia is passed through it for 30 minutes.  The resulting mixture is stirred for 1 hour at -15 ° C and then dared is poured into a vessel containing 200 ml of ice.  The aqueous solution is extracted with ethyl acetate.  The organic layer is separated and washed successively with 1.5N.  citric acid solution, water, 1 n.  sodium bicarbonate solution and water.  The ethyl acetate layer was separated and dried over magnesium sulfate, evaporated in vacuo to give the title compound.  AT.  s -tr.  -butyloxycarbonyl-tyrosyl-B-alanyl-glycyl-S-n-propyl-b-phenylalanilamide.  One equivalent is added to 20 ml of freshly prepared 1N solution of anhydrous HCB in glacial acetic acid / containing 2 ml of anisole. tert -butyloxycarbonyl-S-n-about drank-b-phenylalanilamide.  The mixture obtained is outweighed at room temperature for 30 minutes, then poured into ether and the precipitate formed is collected and dried.  The hydrogen chloride salt is then dissolved. in 30 ml of DMF.  The solution is cooled before and one equivalent of N-tert, butyloxycarbonyl-O-benzyl-b-tyrosyl-O-alanyl-glycine {obtained as in example 1 D) is added, one equivalent of HAT is 1 equivalent of DSS. Then the reaction mixture was stirred at for 2 h and at 4 ° C for 1 day. The mixture is cooled before and filtered.  The filtrate is concentrated in vacuo to an oil, which is redissolved in ethyl acetate. Ethyl acetate The solution is washed with an additional 1N sodium bicarbonate solution, water, and a cold 0.7N solution.  citric acid solution with water.  The organic phase is dried over magnesium sulphate and concentrated in vacuo to an oil.  The oil is chromatographed on a 3 X 40 cm column with silica gel in chloroform.  The product was eluted using a step gradient of chloroform in a mixture of 10% methanol in chloroform. The course of chromatography was followed by chromatography on a thin layer of selected fractions. -propyl-b-phenylalanilamide.  The product obtained is dissolved in 60 ml of ethanol and 1.5 g of palladium (5%) on coal is added to the mixture in the form of an aqueous suspension. Nitrogen is passed through the gas distribution tube to the reaction mixture for 5 minutes and then hydrogen for 6 hours.  The reaction mixture is then purged with i3OTOM and the palladium catalyst removed by filtration.  The mixture is concentrated in vacuo to a syrupy state.  The syrup is dissolved in chloroform and purified by chromate graph on a 40 x 3 cm silica gel column.  The product was eluted using a step gradient of chloroform in a mixture of 10% methanol in chloroform, and the thinning-profile of the selected fractions was isolated according to the thin-layer profile to give the compound, molecular weight 597.7, oi — 34.8 (C 0.5 methanol ).  Elemental analysis: Calculated,%: C 62.29; H 7.25; N 11 Се1 Н43 ЩО-; Found,%: C 62.13; H 7.24; N 11 G.  L-tyrosyl-O-alanyl-glycyl-K 1-propyl-1 | -phenylalanilamide, acetate 800 mg of the product obtained (1.34 mmol) is dissolved in 10 ml of trifluoroacetic acid containing 0.5 ml of anisole.  The mixture is stirred at 30 minutes.  The reaction mixture is dried by lyophilization.  The solid is dissolved in a sufficient amount of an aqueous buffer solution (1% pyridine and 0.5% acetic acid), the volume is brought to 10 ml; the solution is pedated onto a 2.5 x 99 cm column with DEAE-Sephadex A-25 (acetate), which is equilibrated with the same buffer, the eluate is viewed at 280 nm and the corresponding fractions are combined and lyophilized.  Repeated lyophilization from 1 M acetic acid solution gives 655 mg of the compound, -11.0 ° (C 0.5, 1 N, HCP solution), Molecular weight 557.6, Elemental analysis: Calculated,%: C 60.31; H 7.05: N12.56 C2gH39% 07 Found; C, 60.23; H, 6.98; N 12.49 Amino acid analysis.  Tug 0.99J Aea 1.00, seu 1.01; NH 0.95.  EXAMPLE 4 Preparation of L-Thirosyl-D-alanyl-glycyl-No. Ethyl-L-phenyl-aryl-amide, Acetate Salt, A, N-Butyloxycarbonyl-N-ethyl-L-Phenyl A-Lane, 10.6 g (0.04 mol) No. of butyloxycarbonyl-b-phenylalanine. The resulting mixture is added dropwise over 30 minutes to a mechanically stirred suspension of 0.12 mol of potassium hydride in 220 ml of tetrahydrofuran and 0.5 g of 18-crown ether. at Oc under nitrogen atmosphere.  The mixture is stirred for an additional 10 minutes while, then a solution of 19.4 ml (0.24 mol) of ethyl iodide in 40 ml is added dropwise over 20 minutes.  tetrahydrofuran.  The mixture was incubated for 4 hours at 0 ° C. Another 19.4 ml (0.24 mol) of ethyl iodide was added to the mixture in two equal portions.  The mixture was stirred for an additional 2 hours and then 10 ml of glacial acetic acid was added.  After stirring for 10 minutes, the mixture is poured onto 400 ml of crushed ice, the pH of the resulting aqueous phase is increased to 8.0 by the addition of 2N sodium hydroxide solution.  The aqueous mixture is extracted twice with ether and then acidified to pH 2.5 by the addition of cold 2N.  hydrochloric acid solution.  Then c. The ordinary mixture is extracted with ethyl acetate, the extract is washed with water, dried over magnesium sulphate and evaporated in vacuo to a syrup.  The syrup is dissolved in 200 ml of ether and 8 ml (0.04 mol) of DCHA are added. The precipitate is filtered off and the filtrate is extracted with 1/5 n.  a solution of citric acid and water.  The ether layer is dried. over magnesium sulfate and evaporated in vacuo to give 4.6 g (39% of theory) of the compound.  NMR spectrum: cf (phenyl) 7.2; {f (Me, SOS-) 1.4.  B.  N -t. -butyloxycarbonylN-ethyl-b-phenylalanilamide.  4.3 g of the obtained α-butyloxycarbonyl-L-ethyl-b-phenylalanyl (0.0416 mol) is dissolved in 60 ml of DMF.  The mixture is cooled to 0 ° C and 3.0 g (0.0166 mol DSS) are added to it.  The reaction mixture is stirred for 2 hours at and then 72 hours at room temperature.  The mixture is then cooled before and filtered. The filtrate is concentrated in vacuo to an oil, which is redissolved in ethyl acetate.  The solution is extracted with 1 and.  sodium bicarbonate solution, water, cold 1.5 n.  solution of monic acid and water.  The organic phase is dried over magnesium sulphate and concentrated to obtain 3.33 g (91% of theory) of the compound — 101.51 (C 1, methanol).  Molecular weight 292.4.  Elemental analysis: Calculated,%: C, 65.73; H, 8.27; N 9; C eH24: 2. C3 Found,%: C 66.03; H 8.13; N 9, B.  H ethyl-b-phenylalanilamide; hydrochloride salt.  3.5 g of the obtained compound (11.95 mol) is dissolved in 40 ml of freshly prepared acetic acid containing anhydrous hydrogen chloride (1N.  solution) and 1.5 ml of anisole and (C, -) SiH.  The reaction mixture is stirred at room temperature for 30 minutes and then poured into ether.  The precipitated product is filtered off and dried, 2.6 g (96% of theory) of the compound are obtained, t.  square  276 - 211 ° C.  Molecular weight 227.7.  Elemental Calculated,%: C 58.02; H 7.08; N 12 C AND-f N2. C2 Found,%: C 57.97; H 7.26; N 12 G.  N-tert. -butyloxycarbonylL-tyrosyl-D-alanyl-glycyl-N ethylL-phenylalaninamide.  1.14 g (0.005 mol) of M ethyl-b-phenyl-alan amide was added to 50 ml of DMF as a hydrochloric salt.  The mixture is cooled to 0 ° C and then 2.95 g (0.005 mol) of DCHA salt is added.  -butyloxycarbonyl-tirsyl-O-alanyl-glycine.  The reaction mixture is stirred at 5 minutes and then 675 (0.005 mol) MBT and 1.03 g (0.005 Å DCC) are added to it.  Stirring is continued at 6.5 h and aathem at room temperature for 20 h.  Mix oh. Lying to the OS and filtered.  The filter is concentrated in vacuo to an oil, which is redissolved in ethyl acetate, extracted with 1N.  sodium bicarbonate solution, water, cold 1.5 fj.  citric acid solution and water.  The organic phase is dried over magnesium sulphate and concentrated in vacuo to an oil.  The oil is purified by chromatography on a 3 x 40 cm column with silica gel in chloroform.  The product was eluted using a step gradient of chloroform in a mixture of 15% methanol and chloroform.  The product is isolated according to the thin-layer profile of the selected fractions to obtain 1.13 g (39% of theory) of the compound, ot 21.0 (C 0.5, methanol).  Molecular weight 583.7.  Elemental analysis: Calculated,%: C 61.73; H 7.08; N 12.0 C30 4 N507 Found;%: C 60.35; H 7v26; N 11.25 D.  L-gyrosyl-O-alanyl-glycyl, N-methyl, L-phenylalanilamide, acetate.  1 g of the obtained product (1.71 mmol) is dissolved in 20 ml of trifluoroacetic acid containing 3 ml of anisole and 3 ml (C. } - ,, SiH.  The mixture was stirred at 0 ° C for ZOmin and poured into ether which precipitated out, the product was filtered and dried (660 mg).  The solid was dissolved in a small amount of a buffered aqueous solution (1% pyridine and 0.05% acetic acid), the volume was made up to 10 ml and this solution was fed to a 2.5 x 90 cm column with DEAE-Sephadex A-25 (acetate ), which is pre-balanced with the same buffer.  The eluate was observed at a wavelength of 280 nm and the corresponding fractions were collected and lyophilized.  The solid solution is dissolved in 0.  , 2M solution of acetic acid (10 ml) and.  the solution is purified by chromatography on a 2.5 x 99 cm column with Sephadex G-10, which is pre-equilibrated with the same solvent.  The eluate was observed at a wavelength of 280 nm and the corresponding fractions were combined and lyophilized to obtain 448 mg (48% of theory) of compound 10.6 (C 0.5, 1 n.  solution of it).  Molecular weight 543.6.  Elemental analysis: Calculated,%: C 59.65; H 6.86; N 12.88 Ca7Ne7M5-07; found,%: C 59.41; H 7.26; N 13.18 Amino acid analysis: Tug 1.03; Aba 0.99; Ceu.  0.97; NH 0.98.  The anesthetic activity of the compounds of formula 1 was studied in experiments with mice on a hot plate.  The mouse is placed in a vertical acrylic cylinder, at the base of which there is a hot plate, the temperature of which is maintained at 52 ° C.  Mouse gets subcutaneous
    injecting a given amount of the test compound dissolved or suspended in the appropriate vehicle. A predetermined period of time has been maintained after the test compound has been introduced, and then the mouse is placed tj the surface of hot platinum. Then record the latencies of two separate events in seconds. The latency is measured first until the paws begin to lick the hind legs, and then the latency is measured until the mouse jumps off the hot plate. A substance that exhibits anesthetic activity provides an increase in these latent periods compared to control mice that were injected with only
    carrier. This should occur at a dose that does not cause impairment of motor coordination or disables the mouse.
    In tab. 1 shows the latency of 5 until the hind legs lick, and in table. 2 - flight escape latency. The criterion of a positive anesthetic effect is as follows: latency moment
    0 hind legs or flight leaps must be equal to or greater than the average control latency plus two standard deviations from the mean. Each result is shown in Table. 1 and 2 is the mean plus or minus standard deviation.
    Table
    15 26.4il, 8 32.9 ± 2.3 32.4t2.4
     26, 7
    30.2 ± 2.7 32.0 ± 2.7 42.2 ± 3.9 15 .25.7 ± 1, .1
    Continuation of table 1
    Ro
    35.2 ± 2.7 58, li5, l
    54.2i: 7.2 240, OtO
    Tavlitsa2
    B-Tyrosyl-O-alanyl-gl cycl-K methyl-b-fennalanilampl, acetate
    9080,5 ± 8,8
    1-J73, 9 126.2il4.7
    : .62,7i9, l lC7, ei8, l
    ,, 2
    L: 13, 5 Ii 62.9i-10.3
    30 73, i; tl4,6
    -0 73,, 6
    63,, 1 130.7 ± 15,
    60 59,
    90 59,, 8 120 79,4t5,7. - .. 120 69,8i4,2
    ;; l- l "and; -; n: s 62,7,7 ,. 118 ,, i2o, 6tu.2
    propyl-b-phenyl 15 75, Gt5,7
    nylamide, acetate
    :;: l :: litsi; ° "-, 8.7.7 121.2115.7-X85,, o
    ethyl-b-phenyl15 7q.li7,7
    nylamide, acetate Note. with.
    lJ3, ltl4.8 222.2 ± 9, l 140,, 0
    237, 7 189.2112.8 105, 2 110,219.8
    104,, 0
    152., 4irl7,5 22Г,, J17,7
    112.2t21.2 144,, 2
    I
    218, ЗГ16,4 69,4tl6,
    89,4t7, .5 104, Its, "126,4-11,7
    I55.0tl7.9 237,, 4
    218, 2, 240, Oio Index 1–3 indicate that the result is significant with the confidence value of V 0.001; P 0.05 and P 0.05, respectively.
    权利要求:
    Claims (3)
    [1]
    Invention Formula
    I. The method of obtaining derivatives of tetrapeptides of formula I
    „O, oW“,
    LF L I
    ; H-CH-t-NH-CH c-NH-vn.- sn-s-z
    H
    L and D mean chirality; R - primary alkyl R / j - hydrogen or primary
    alkyl Cz;
    Ra is hydrogen or primary alkyl CM;
    Z is CONH (with the proviso that one of the radicals is Qu and Rj is primary alkyl, the second is hydrogen),
    or salts thereof, characterized in that the protected compounds corresponding to the tetrapeptide derivatives of the formula I are deblocked by treatment in an acidic medium.
    [2]
    2. The method according to claim 1, wherein the release is carried out in trifluoroacetic acid.
    [3]
    3. A method according to claim 1, characterized in that the release is carried out in glacial acetic acid saturated with gaseous HCC.
    Sources of information taken into account during the examination 1. Schroeder E., Lubke K. Peptides,
    World
    Part 1, 1967, M ,,
    s, 112.
    类似技术:
    公开号 | 公开日 | 专利标题
    KR850001269B1|1985-09-04|Process for preparing aminoacid derivatives
    SU908246A3|1982-02-23|Process for producing tetrapeptide derivatives or their salts
    NZ244985A|1995-06-27|Peptide compounds, preparation and pharmaceutical compositions thereof
    FR2575753A1|1986-07-11|NOVEL PEPTIDE DERIVATIVES WITH A NITROGEN POLYCYCLIC STRUCTURE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    HU190486B|1986-09-29|Process for producing spiro /4./3+n// -2-azaalkane-3-carboxylic acid-derivatives and pharmaceutical compositions containing the same
    CA1201710A|1986-03-11|Analgesic compounds
    US4401658A|1983-08-30|Tri-, tetra, and penta-peptides, their preparation and compositions containing them
    SE447389B|1986-11-10|NEW TRIPEPTIDES AFFECTING THE CENTRAL NERVOUS SYSTEM
    HU186983B|1985-10-28|Process for preparing new 3-amino-5-pregnene derivatives and salts thereof
    EP0074787B1|1985-03-27|Renally active dipeptides
    US4797471A|1989-01-10|Peptide derivatives having an inhibitory action on hydroxylating enzymes, a process for their preparation, agents containing them, and their use
    US4439448A|1984-03-27|Glutamine derivatives
    KR900003515B1|1990-05-21|Heptanoyl-gil-asp-ala-amino acid humunostimulants
    US4387049A|1983-06-07|Adamantyl containing peptides
    US3853834A|1974-12-10|4-alanine lh-rh analog
    CA2070983A1|1992-12-12|Cyclic renin inhibitors
    US3299035A|1967-01-17|L-aspartyl-l-alanyl-l-phenylalanyl-l-isoleucyl-glycyl-l-leucyl-l-methioninamide and its acid addition salts
    EP0121830A2|1984-10-17|Substituted dipeptides as antihypertensives
    SU993816A3|1983-01-30|Process for preparing octapeptides
    US4093713A|1978-06-06|Dipeptide derivatives with central nervous system activity and preparation thereof
    US4331593A|1982-05-25|Analgesic compounds
    CA1247083A|1988-12-20|Peptide, process for preparation thereof and usethereof
    US4102878A|1978-07-25|Process for the preparation of the cholecystokinin-pancreozymin octapeptide amide sulfate ester
    US3948971A|1976-04-06|N-protected-α-amino acid compounds
    HU220875B1|2002-06-29|Pentapeptide derivative, production thereof and their intermediates
    同族专利:
    公开号 | 公开日
    DK434778A|1979-04-04|
    EP0001684A3|1979-06-27|
    DD139710A5|1980-01-16|
    FR2404629B1|1985-12-27|
    IT7828359D0|1978-10-02|
    FI66842C|1984-12-10|
    EP0001684A2|1979-05-02|
    IT1100839B|1985-09-28|
    CA1156219A|1983-11-01|
    PT68598A|1978-10-01|
    AU520315B2|1982-01-28|
    NZ188521A|1981-07-13|
    DE2861019D1|1981-11-26|
    ES473925A1|1980-01-16|
    IE47378B1|1984-03-07|
    EP0001684B1|1981-09-02|
    YU231578A|1982-10-31|
    IE781926L|1979-04-03|
    PL114271B1|1981-01-31|
    FR2404629A1|1979-04-27|
    ATA708778A|1981-10-15|
    LU80316A1|1979-03-16|
    EG13636A|1982-03-31|
    AU4024778A|1980-04-03|
    GB2005688A|1979-04-25|
    GR71651B|1983-06-20|
    DK149231B|1986-03-24|
    CH635571A5|1983-04-15|
    US4264491A|1981-04-28|
    DK149231C|1986-08-18|
    AT367028B|1982-05-25|
    BG31224A3|1981-11-16|
    ZA785564B|1980-05-28|
    AR224238A1|1981-11-13|
    RO76176A|1981-11-04|
    JPS5459247A|1979-05-12|
    CS235072B2|1985-04-16|
    BE870819A|1979-03-28|
    HU182866B|1984-03-28|
    GB2005688B|1982-02-24|
    FI782971A|1979-04-04|
    IL55650A|1982-02-28|
    PL210045A1|1979-06-18|
    PH14660A|1981-10-20|
    FI66842B|1984-08-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1042487A|1964-06-25|1966-09-14|Ici Ltd|Polypeptide derivatives|
    HU184704B|1976-01-26|1984-10-29|Wellcome Found|Process for preparing biologically active encephaline analogues|
    DK28377A|1976-02-02|1977-08-03|Sandoz Ag|PROCEDURE FOR PREPARING POLYPEPTIDE DERIVATIVES|
    GB1532181A|1976-02-02|1978-11-15|Beckman Instruments Inc|Pentapetides and a method of preparing them|
    US4028319A|1976-05-07|1977-06-07|G. D. Searle & Co.|2 and 3-substituted enkephalins|
    DE2732451A1|1976-07-27|1978-02-02|Reckitt & Colmann Prod Ltd|Peptide morphine agonists - for use as analgesics, sedatives, antitussives, etc.|
    FR2359817B1|1976-07-27|1981-01-02|Reckitt & Colmann Prod Ltd|
    US4259234A|1976-09-27|1981-03-31|Eli Lilly And Company|Analgesic compounds|DK28377A|1976-02-02|1977-08-03|Sandoz Ag|PROCEDURE FOR PREPARING POLYPEPTIDE DERIVATIVES|
    US4331593A|1977-10-03|1982-05-25|Smithwick Jr Edward L|Analgesic compounds|
    US4265808A|1979-12-17|1981-05-05|Eli Lilly And Company|Pharmacologically active peptides|
    US4333873A|1979-12-17|1982-06-08|Eli Lilly And Company|Pharmacologically active peptides|
    US4283330A|1979-12-17|1981-08-11|Eli Lilly And Company|Pharmacologically active peptides|
    JPS6340199B2|1979-12-27|1988-08-10|Takeda Chemical Industries Ltd|
    FR2488253B1|1980-08-08|1984-01-27|Roques Bernard|
    JPH0115520B2|1980-08-18|1989-03-17|Earth Chemical Co|
    US4322340A|1980-10-20|1982-03-30|Eli Lilly And Company|Pharmacologically active peptides|
    JPH0445517B2|1980-10-24|1992-07-27|Takeda Chemical Industries Ltd|
    JPS5785349A|1980-11-14|1982-05-28|Earth Chem Corp Ltd|Tripeptide alkylamide derivative|
    EP0076557B1|1981-06-22|1985-11-13|Imperial Chemical Industries Plc|Peptides and pseudopeptides in which the n terminus bears two substituents|
    US4448717A|1982-11-12|1984-05-15|Eli Lilly And Company|Pharmacologically active peptides|
    US4495178A|1983-10-06|1985-01-22|G. D. Searle & Co.|Enkephalin analogs|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/838,516|US4264491A|1977-10-03|1977-10-03|Analgesic compounds|
    [返回顶部]